Trial · NCT03480243
Results by group167
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 167
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Padsevonil for Single Dose | Padsevonil (Period 1) (PK-PPS) | 366.6 | Geometric Coefficient of Variation 38.8 | ng/mL | |
| Maximum Observed Plasma Concentration (Cmax) of Padsevonil for Single Dose | Padsevonil (Period 2) (PK-PPS) | 385.3 | Geometric Coefficient of Variation 40.9 | ng/mL | |
| Maximum Observed Plasma Concentration (Cmax) of Padsevonil for Single Dose | Padsevonil and Erythromycin (Period 3b) (PK-PPS) | 697.4 | Geometric Coefficient of Variation 46.9 | ng/mL | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC(0-12)) of Padsevonil for Single Dose | Padsevonil (Period 1) (PK-PPS) | 1428 | Geometric Coefficient of Variation 40.7 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC(0-12)) of Padsevonil for Single Dose | Padsevonil (Period 2) (PK-PPS) | 1571 | Geometric Coefficient of Variation 41.8 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC(0-12)) of Padsevonil for Single Dose | Padsevonil and Erythromycin (Period 3b) (PK-PPS) | 2576 | Geometric Coefficient of Variation 47.0 | hours*ng/mL | |
| Maximum Observed Steady-state Plasma Concentration (Cmax, ss) of Padsevonil for Multiple Doses | Padsevonil (Period 1) (PK-PPS) | 475.0 | Geometric Coefficient of Variation 38.4 | ng/mL | |
| Maximum Observed Steady-state Plasma Concentration (Cmax, ss) of Padsevonil for Multiple Doses | Padsevonil (Period 2) (PK-PPS) | 473.9 | Geometric Coefficient of Variation 43.7 | ng/mL | |
| Maximum Observed Steady-state Plasma Concentration (Cmax, ss) of Padsevonil for Multiple Doses | Padsevonil and Erythromycin (Period 3b) (PK-PPS) | 1010 | Geometric Coefficient of Variation 45.7 | ng/mL | |
| Area Under the Plasma Concentration-time Curve Over a Dosing Interval (12 Hours) (AUCtau) of Padsevonil for Multiple Doses | Padsevonil (Period 1) (PK-PPS) | 2049 | Geometric Coefficient of Variation 41.1 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve Over a Dosing Interval (12 Hours) (AUCtau) of Padsevonil for Multiple Doses | Padsevonil (Period 2) (PK-PPS) | 2274 | Geometric Coefficient of Variation 47.1 | hours*ng/mL | |
| Area Under the Plasma Concentration-time Curve Over a Dosing Interval (12 Hours) (AUCtau) of Padsevonil for Multiple Doses | Padsevonil and Erythromycin (Period 3b) (PK-PPS) | 5073 | Geometric Coefficient of Variation 55.9 | hours*ng/mL | |
| Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Single Dose | Padsevonil (Period 1) (PK-PPS) | 3.000 | Full Range 1.00 to 4.05 | hours | |
| Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Single Dose | Padsevonil (Period 2) (PK-PPS) | 1.500 | Full Range 0.500 to 4.00 | hours | |
| Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Single Dose | Padsevonil and Erythromycin (Period 3b) (PK-PPS) | 1.500 | Full Range 0.750 to 3.02 | hours | |
| Minimum Observed Plasma Concentration (Cmin) of Padsevonil for Single Dose | Padsevonil (Period 1) (PK-PPS) | 2.857 | Geometric Coefficient of Variation 100.9 | ng/mL | |
| Minimum Observed Plasma Concentration (Cmin) of Padsevonil for Single Dose | Padsevonil (Period 2) (PK-PPS) | 5.643 | Geometric Coefficient of Variation 147.8 | ng/mL | |
| Minimum Observed Plasma Concentration (Cmin) of Padsevonil for Single Dose | Padsevonil and Erythromycin (Period 3b) (PK-PPS) | 4.286 | Geometric Coefficient of Variation 172.5 | ng/mL | |
| Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Multiple Doses | Padsevonil (Period 1) (PK-PPS) | 1.750 | Full Range 0.500 to 4.00 | hours | |
| Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Multiple Doses | Padsevonil (Period 2) (PK-PPS) | 1.500 | Full Range 0.500 to 4.00 | hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03480243/results